Treatment for Outpatients with Comorbid Schizophrenia and Substance Use Disorders: A Review

By  

European Addiction Research, Vol. 20, Iss. 3, 2013-10 ,pp. : 105-114

Karger

Access to resources Recommend Favorite

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

By Kozma Chris M.   Slaton Terra   Dirani Riad   Fastenau John   Gopal Srihari   Hough David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1603-1611

Informa Healthcare

Access to resources Recommend Favorite

A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)

By Wolf Jürgen   Janssen Firmin   Lublin Henrik   Salokangas Raimo KR   Allain Hervé   Smeraldi Enrico   Bernardo Miguel   Millar Helen   Pans Miranda   Adelbrecht Christine   Laughton Jim   Werner Christian   Maier Wolfgang  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2313-2323

Informa Healthcare

Access to resources Recommend Favorite

Substance Use Disorders and Comorbid Mental Disorders in First-Time Admitted Patients from a Catchment Area

By  

European Addiction Research, Vol. 18, Iss. 1, 2011-10 ,pp. : 16-25

Karger

Access to resources Recommend Favorite

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders

By Kollins Scott H.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1345-1357

Informa Healthcare

Access to resources Recommend Favorite